Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

autoimmunity

- PMLiVE

Permission to pause: making treatment breaks part of the cancer care conversation

Exploring how empathetic, patient-centred communication can make planned treatment breaks easier to discuss as part of cancer care.

Cuttsy + Cuttsy

- PMLiVE

Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn

The companies will aim to discover new antibody-based therapeutics for cancer

- PMLiVE

GSK and Vesalius partner on new Parkinson’s treatments in deal worth $650m

The alliance is aimed at developing treatments for Parkinson's and another neurodegeneration indication

- PMLiVE

Common antidiabetic drug metformin found to slow growth of precancerous cells

The findings suggest that the drug could be used to manage squamous oesophageal cancer risk

- PMLiVE

New genomic technique could improve antibiotic-resistant bacteria tracking in hospitals

The sequencing method is able to track the spread of multiple bacteria at the same time

- PMLiVE

Innovative Trials Announces New Charity Partnerships

Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year

Innovative Trials

- PMLiVE

Study identifies thousands of high-risk cancer gene variants and potential therapeutic target

Patients with inherited variants of the BAP1 gene have a 50% increased risk of developing certain cancers

- PMLiVE

Eli Lilly and Radionetics Oncology enter $140m radiopharma partnership

The strategic agreement also gives Lilly the exclusive right to acquire the biotech for $1bn

- PMLiVE

Envision Analogue – An Introduction

Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

Genesis Research Group

- PMLiVE

New study aims to identify IBD biomarkers for personalised medicine

The chronic gastrointestinal condition affects more than 540,000 people in the UK

- PMLiVE

Ipsen enters $900m licensing agreement for Sutro Biopharma’s ADC candidate

STRO-003 will be the first ADC candidate to be added to Ipsen’s portfolio

- PMLiVE

Single genetic test could replace current standard for diagnosing rare developmental disorders

The single genetic test could potentially replace the current standard and reduce costs for the NHS

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links